Navigation Links
MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
Date:5/13/2008

$2,394,010 $1,773,037

Costs and expenses:

Cost of product sales 621,440 233,635

Research and development 3,727,859 7,528,872

Selling, general and administrative 4,753,326 7,688,652

Total expenses 9,102,625 15,451,159

Loss from operations (6,708,615) (13,678,122)

Interest income 125,282 134,027

Interest expense - (193,895)

Warrant expense (7,440,000) -

Other income (expense) (19,074) 75,000

Loss including noncontrolling

interest $(14,042,407) $(13,662,990)

Loss attributable to noncontrolling

interest 242,905 0

Net loss (13,799,502) (13,662,990)

Basic and diluted net loss per share $(0.26) $(0.38)

Shares used in calculation of basic

and diluted net loss per share 53,295,303 36,383,312

MIDDLEBROOK PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

March 31, December 31,

2008 2007

ASSETS

Current assets:

Cash and cash equivalents $17,957,034 $1,951,715

Accounts receivable, net 765,003 687,787

Inventories, net 373,324 687,933

Prepaid expenses and other

current ass
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...ears Even Though Some Kilns Emit More,Mercury Than...L, CA, IA,IL, MD, MI, MT, NY, OR, SC, TX and WA.,... For more than a decade,after Congress told it to ... across the nation, the U.S. Environmental Protect...w study from Earthjustice and the,Environmental In...
(Date:7/23/2008)... Biodiversity has long been recognized by EPA as c... on healthy ecosystems to provide food, clean air,...onnection between disease and biodiversity (the nu...geographic region). Recent studies suggest that m...eases such as Lyme disease and West Nile encephali...
(Date:7/23/2008)...e/ -- Mercy Health Plans, the St.,Louis-based heal...the,Sisters of Mercy Health System, has announced ...plans to: Mercy MedicareAdvantage. The plans, whic...d Southwest Missouri,previously were offered usin...John,s PremierPlus and St. John,s PremierPlus Opti...
(Date:7/23/2008)...knowledge that regular exercise supports physical ...tions from health care providers, the majority of ...n a new study, University of Missouri researchers ...d interventions focused on behavior-changing strat...ity levels. In contrast, interventions based on co...
Breaking Medicine News(10 mins):Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 2Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 3Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 4Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 5Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 6Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 7Health News:Could preserving biodiversity reduce disease? 2Health News:Making patients move requires the right exercise advice 2
...ated injury experts from eight countries that have... and discussed their emergency medical response to...uld be used by others to enhance preparedness. Th..., Indonesia, Iraq, Israel, United Kingdom, United ...
...FDA) today announced that manufacturers of pergoli...n’s disease, will voluntarily remove// these drugs...mage to patients’ heart valves. The products bein... for pergolide marketed by Valeant Pharmaceuticals...
...ster have discovered that arthritis pain, unlike t... in the //parts of the brain concerned with emotio...captured the first images of how the brain process...sion tomography (PET) scanners based at the Christ...
...ss has said the country’s healthcare sector would ... New avenues of opportunity within healthcare itse...icant growth driver, the minister said while addre... students and researchers at the Boston University...
Other Medicine News:Health News:International Study Finds Ways to Maximize Effective Responses After Terrorism Incidents 2Health News:International Study Finds Ways to Maximize Effective Responses After Terrorism Incidents 3Health News:FDA Announces Voluntary Withdrawal of Pergolide Products 2Health News:Arthritis Pain Processed in Brain’s 'fear Zone,' First PET Scans Revea 2
(Date:7/23/2008)... Company Focused on IND-Enabling Work with Protei... Pathway of Complement System, CAMBRIDGE, Mass., ...today announced it has initiated a corporate growt...D., as chief executive officer and the,establishme...niker succeeds,Woodruff Emlen, M.D., a co-founder ...
(Date:7/22/2008)... Latest awards under Therapeutics Development Ini...borations to 23; next deadline January 20,2009, ...rt of its mission to,speed delivery of transformat... The Michael J. Fox Foundation for Parkinson,s Res... six industry research teams. The awards,were gran...
(Date:7/22/2008)... Two Regimens Including Lantus(R) and Apidra(R) Re...ts with Type 2 Diabetes, Whatever the Algorithm ... N.J., July 22 /- Results from the "A...a Simple Algorithm to Carbohydrate,Counting for Ad...e,published in the American Diabetes Association,s...
(Date:7/22/2008)...st Developed and Validated by Columbia University ..., Proprietary MicroRNA Technology, The Test Diff...ll Lung Cancer (NSCLC), Classifying Squamous-Cell...96 Percent and Specificity of 90 Percent,This is t...NAs, Sensitivity as Biomarkers for Accura...
Breaking Medicine Technology:Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Invasion of the brain tumors 41 1Features of replication suggest viruses have common themes vulnerabilities 38 1Features of replication suggest viruses have common themes vulnerabilities 38 2Features of replication suggest viruses have common themes vulnerabilities 38 3Clones on task serve greater good evolutionary study shows 35 1Clones on task serve greater good evolutionary study shows 35 2Unravelling new complexity in the genome 32 1Unravelling new complexity in the genome 32 2
...rtments, REINACH and BASEL, Switzerland, March 29,...announced promising,results of "first-in-man" stud...se studies included a total of 19 healthy male,vol...ever using Microdosing,for the determination of dr...s showed that AR-709 achieves high concentrations ...
...ADIA Pharmaceuticals,Inc. (Nasdaq: ACAD), a biopha...y to fuel drug discovery and clinical,development ...orders, today announced that the company will pres...renia Research, held from,March 28 through April 1...ns will cover ACADIA,s two schizophrenia programs ...
Other Medicine Technology:Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 2ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 3ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 4ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 5
...g; medication nebulizer achieves optimum lung pene...d MMAD particle size range is 1.04-1.10 µ at...essor or air outlet., ,As the world leader in air...providers the assurance of proven technology by of...
...rs breakthrough continuous low-flow nebulizer perf...ozzle technology allows for optimal medication and...I~NEB takes on severe asthma, COPD and pneumonia i...gure with a mask, mouth and T-piece to deliver hig...
...ication nebulizers offer a spill-proof design and ... angle. All medical nebulizers are free-standing f...ations are available., ,All Portex® medicatio...g; medication nebulizers feature consistently fine...
...ication nebulizers offer a spill-proof design and ... angle. All medical nebulizers are free-standing f...ations are available., ,All Portex® medicatio...g; medication nebulizers feature consistently fine...
Medicine Products: